

## United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/773,124	02/05/2004	Mark A. Tracy	1733.1045-008	3258
21005	7590 11/24/2004		EXAM	INER
HAMILTON	I, BROOK, SMITH	WEBMAN, EDWARD J		
530 VIRGINI. P.O. BOX 913			ART UNIT	PAPER NUMBER
CONCORD,	MA 01742-9133		1617	
			DATE MAILED: 11/24/200	4

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No. Applicant(s)		
	10/773124 TRACY		
Office Action Summary	Examiner Group Art Unit		
	W63 mM 1617		
—The MAILING DATE of this communication app	ears on the cover sheet beneath the correspondence address—		
Period for Reply			
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET OF THIS COMMUNICATION.	T TO EXPIRE MONTH(S) FROM THE MAILING DATE		
from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a  - If NO period for reply is specified above, such period shall, by defa	R 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS a reply within the statutory minimum of thirty (30) days will be considered timely. Ault, expire SIX (6) MONTHS from the mailing date of this communication. Attaute, cause the application to become ABANDONED (35 U.S.C. § 133).		
Status			
Responsive to communication(s) filed on	15/04		
☐ This action is FINAL.			
<ul> <li>Since this application is in condition for allowance exce accordance with the practice under Ex parte Quayle, 1</li> </ul>	ept for formal matters, <b>prosecution as to the merits is closed</b> in 935 C.D. 1 1; 453 O.G. 213.		
Disposition of Claims			
XClaim(s) 1 — 4	is/are pending in the application.		
Of the above claim(s)	is/are pending in the application. is/are withdrawn from consideration.		
☐ Claim(s)			
Claim(s) 1-4	is/are rejected.		
☐ Claim(s)————————————————————————————————————			
	are subject to restriction or election		
Application Papers	requirement.		
Application apers	ving Review PTO-948		
☐ See the attached Notice of Draftsperson's Patent Draw	ving Neview, 1 10 340.		
☐ See the attached Notice of Draftsperson's Patent Drav ☐ The proposed drawing correction, filed on	is □ approved □ disapproved.		
<ul> <li>□ See the attached Notice of Draftsperson's Patent Drav</li> <li>□ The proposed drawing correction, filed on is/are object.</li> </ul>			
☐ The proposed drawing correction, filed on			
☐ The proposed drawing correction, filed on is/are ob	jected to by the Examiner.		
<ul> <li>□ The proposed drawing correction, filed on is/are ob</li> <li>□ The drawing(s) filed on is/are ob</li> <li>□ The specification is objected to by the Examiner.</li> <li>□ The oath or declaration is objected to by the Examiner</li> </ul>	jected to by the Examiner.		
<ul> <li>□ The proposed drawing correction, filed on is/are ob</li> <li>□ The drawing(s) filed on is/are ob</li> <li>□ The specification is objected to by the Examiner.</li> <li>□ The oath or declaration is objected to by the Examiner</li> <li>Priority under 35 U.S.C. § 119 (a)-(d)</li> <li>□ Acknowledgment is made of a claim for foreign priority</li> <li>□ All □ Some* □ None of the CERTIFIED copies</li> <li>□ received.</li> </ul>	jected to by the Examiner.  r.  r under 35 U.S.C. § 11 9(a)-(d).  of the priority documents have been		
<ul> <li>□ The proposed drawing correction, filed on is/are objected to by the Examiner.</li> <li>□ The specification is objected to by the Examiner.</li> <li>□ The oath or declaration is objected to by the Examiner</li> <li>Priority under 35 U.S.C. § 119 (a)-(d)</li> <li>□ Acknowledgment is made of a claim for foreign priority</li> <li>□ All □ Some* □ None of the CERTIFIED copies</li> </ul>	jected to by the Examiner.  r.  r under 35 U.S.C. § 11 9(a)-(d).  of the priority documents have been  mber)		
<ul> <li>□ The proposed drawing correction, filed on is/are ob</li> <li>□ The drawing(s) filed on is/are ob</li> <li>□ The specification is objected to by the Examiner.</li> <li>□ The oath or declaration is objected to by the Examiner</li> <li>Priority under 35 U.S.C. § 119 (a)-(d)</li> <li>□ Acknowledgment is made of a claim for foreign priority</li> <li>□ All □ Some* □ None of the CERTIFIED copies</li> <li>□ received.</li> <li>□ received in Application No. (Series Code/Serial Nur</li> </ul>	jected to by the Examiner.  y under 35 U.S.C. § 11 9(a)-(d). of the priority documents have been  mber)  International Bureau (PCT Rule 1 7.2(a)).		
<ul> <li>□ The proposed drawing correction, filed on</li></ul>	jected to by the Examiner.  y under 35 U.S.C. § 11 9(a)-(d). of the priority documents have been  mber)  International Bureau (PCT Rule 1 7.2(a)).		
<ul> <li>□ The proposed drawing correction, filed on is/are objected to by the Examiner.</li> <li>□ The specification is objected to by the Examiner.</li> <li>□ The oath or declaration is objected to by the Examiner.</li> <li>Priority under 35 U.S.C. § 119 (a)-(d)</li> <li>□ Acknowledgment is made of a claim for foreign priority</li> <li>□ All □ Some* □ None of the CERTIFIED copies</li> <li>□ received.</li> <li>□ received in Application No. (Series Code/Serial Nur</li> <li>□ received in this national stage application from the latent copies not received:</li> </ul> *Certified copies not received: Attachment(s)	jected to by the Examiner.  y under 35 U.S.C. § 11 9(a)-(d). of the priority documents have been  mber)  International Bureau (PCT Rule 1 7.2(a)).		
<ul> <li>□ The proposed drawing correction, filed on is/are objected to by the Examiner.</li> <li>□ The specification is objected to by the Examiner.</li> <li>□ The oath or declaration is objected to by the Examiner.</li> <li>Priority under 35 U.S.C. § 119 (a)-(d)</li> <li>□ Acknowledgment is made of a claim for foreign priority All Some* None of the CERTIFIED copies received.</li> <li>□ received in Application No. (Series Code/Serial Nur received in this national stage application from the limitation.</li> </ul>	jected to by the Examiner.  y under 35 U.S.C. § 11 9(a)-(d). of the priority documents have been  mber)  International Bureau (PCT Rule 1 7.2(a)).		

Application/Control Number: 10/773,124

Art Unit: 1617

Claims 1-7, 15-18 are rejected under 35 U.S.C. 101 as claiming the same invention as that of claims 1-14 of prior U.S. Patent No. 6713087. This is a double patenting rejection.

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 8-14, 19-21 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-15 of U.S. Patent No. 6713087. Although the conflicting claims are not identical, they are not patentably distinct from each other because the patented claims encompass the scope of the instant claims vis-à-vis the ladile compound, the solvents, and the step of adding a metal cation.

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

<sup>(</sup>b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Application/Control Number: 10/773,124

Art Unit: 1617

Claims 22-38, 40-41 are rejected under 35 U.S.C. 102(b) as being anticipated by Johnson et al.

Johnson et al teach stabilized particles of Human growth hormone dispersed in a polymer (abstract). Stabilization with zinc ion is specified (claim 5). Polylactide coglycolide is disclosed (claim 14). Zinc carbonate is specified (column 4 line 39). Polymeric microparticles of 1 micron are disclosed (column 4 line 61).

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claim 39 is rejected under 35 U.S.C. 102(b) as being anticipated by Bernstein et al.

Bernstein et al teach an active agent dispersed in a polymer (abstract), nonbiodegradable polymers are specified (claim 21 ).

No claims allowed.

Any inquiry concerning this communication should be directed to Edward J. Webman at telephone number 571-272-0633.

Webman/tgd

November 2, 2004

Application/Control Number: 10/773,124

Art Unit: 1617

EDWIND J. WEBMAN PRIMARY EXAMINER GROUP 1500